UCB Forecast | Price, Price Target & Analyst Assessment

UCB

ENXTBR:UCB

€ 258,50

+ €5,10 (2,01%)

258,50 €

+€5,10 (2,01%)

End-of-day quote: 03/31/2026

UCB Stock Value

The current analyst recommendation for UCB is: Outperform.

Outperform

UCB Company Info

EPS Growth 5Y

-0,86%

Market Cap

€49,21 B

Long-Term Debt

€2,18 B

Annual earnings

N/A

Dividend

€1,47

Dividend Yield

0,57%

Founded

1925

Industry

Health Care

Country

Belgium

Website

UCB

ISIN Number

BE0003739530

Website

http://www.ucb.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€297,00

14.89%

Last Update: 04/01/2026

Analysts: 20

Highest Price Target €340,00

Average Price Target €297,00

Lowest Price Target €195,00

In the last five quarters, UCB’s Price Target has risen from €121,53 to €209,67 - a 72,53% increase. Seventeen analysts predict that UCB’s share price will increase in the coming year, reaching €297,00. This would represent an increase of 14,89%.

Top growth stocks in the health care sector (5Y.)

What does UCB do?

UCB SA, a biopharmaceutical company, dedicates to the development of innovative medicines and solutions for patients with severe disease. The company’s primary business is rooted in identifying and addressing unmet medical needs, focusing primarily on therapeutic areas such as central nervous system disorders and immunology. The company operates on a global scale, engaging with healthcare systems and professionals to promote its therapies and ensure patient access to them. Business Segments UC...

Business Segments

UCB operates primarily in two main therapeutic areas: neurology and immunology.

In neurology, the company's focus is on conditions such as epilepsy, Parkinson’s disease, and migraine, contributing significantly to the advancement of treatments that address these chronic disorders. UCB’s dedication to neuroscience is evident in its investment in research aimed at uncovering new therapeutic benefits within this domain.

In immunology, UCB is dedicated to developing solutions for patients with autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company prioritizes understanding the underlying mechanisms of these conditions, striving to adopt a patient-centric approach in creating therapies that enhance the quality of life. This dual focus allows UCB to leverage its scientific expertise and position itself uniquely within the competitive biopharmaceutical landscape.

UCB also engages in research and development (R&D) to address disease mechanisms that have historically been challenging to treat. It employs a strategic framework that emphasizes both large-scale clinical trials in various drug development phases and smaller, more targeted studies. Through collaborations, partnerships, and alliances, UCB continues to broaden its product pipeline while enhancing its portfolio's robustness.

Business Strategy

UCB’s business strategy centers on a patient-first philosophy, coupled with a profound commitment to scientific excellence. The company emphasizes the importance of collaboration within the healthcare ecosystem to drive innovation and enhance the effectiveness of its medicines. This strategy is reflected in its extensive partnerships with academic institutions, research organizations, and other pharmaceutical entities.

Moreover, UCB strives to anticipate and respond to market needs, adapting quickly to changes in regulations and healthcare policies worldwide. The company's strategy also underscores its commitment to sustainability — going beyond mere compliance by integrating environmental responsibility into business operations. This focus strengthens UCB's reputation as a responsible corporate citizen while allowing it to contribute positively to global health outcomes.

Products and Services

UCB’s portfolio comprises several established pharmaceutical products and therapeutic solutions designed to address severe diseases. The company offers treatments that are pivotal in the management of conditions such as epilepsy, migraines, and chronic pain associated with neurological disorders. In the realm of immunology, UCB provides innovative therapies that support patients coping with autoimmune conditions.

The company's commitment to R&D fosters the continuous introduction of new products within its therapeutic landscape. Its pipeline includes advanced treatments that are undergoing various stages of clinical trials, poised to meet specific patient needs efficiently. UCB is also focused on the enhancement of existing medicines through reformulations, improved delivery systems, and enhanced patient support programs.

Additionally, the services extended by UCB go beyond pharmaceuticals; it includes comprehensive patient support programs aimed at enhancing treatment adherence and managing disease complications. The company actively engages with healthcare providers to ensure a seamless integration of its therapies into patient care.

Geographical Markets Served

UCB holds a strong presence in both established and emerging markets across the globe, with particular emphasis on Europe and North America, complemented by growing activities in Asia and Latin America. The company’s strategic focus on global market expansion includes adapting its operational model to local contexts, which facilitates better market access and customer engagement.

Seasonality

The demand for its products is influenced more by healthcare trends, regulatory developments, and shifts in disease prevalence rather than by traditional seasonal factors. The company approaches business planning with an understanding of these dynamics to ensure the consistency of its operations and market presence throughout the year.

Customers

UCB serves a diverse array of customers, including healthcare providers, hospitals, clinics, and pharmacies. The company's customer base spans various segments, ranging from specialists in neurology and immunology to general practitioners and public health organizations. By continuously engaging with healthcare professionals, UCB ensures that it remains informed about patient needs while expanding its reach and enhancing its customer relationships.

Sales and Marketing

UCB employs a multifaceted approach to sales and marketing, utilizing various strategies to reach different customer segments effectively. Its marketing strategies encompass direct engagement with healthcare providers through educational initiatives, product demonstrations, and the dissemination of clinical data that underscores the effectiveness of its treatments.

Distribution channels are optimized to ensure that products are readily available to patients across its key markets. UCB collaborates with wholesalers, distributors, and health systems to streamline its supply chain and enhance product accessibility. This integrated distribution model enables the company to adapt quickly to market changes and customer demands, ensuring that patients have continuous access to UCB's innovative therapies.

History

UCB SA was founded in 1925. The company was incorporated in 1925

UCB Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2025) **TOP 3 Markets:** 1. **USA:** approx. 45% 2. **Europe (including Germany, France, UK):** approx. 35% 3. **Japan:** approx. 10% UCB SA is a biopharmaceutical company, with revenues entirely derived from the pharmaceutical industry. The USA represents the large...

At which locations are the company’s products manufactured?

**Production sites of UCB SA:** 1. **Braine-l'Alleud, Belgium** 2. **Bulle, Switzerland** 3. **Raleigh, USA** 4. **Suzhou, China** UCB SA is a globally active biopharmaceutical company headquartered in Brussels, Belgium. The production facilities are strategically located in different regions...

What strategy does UCB pursue for future growth?

**Focus on Research and Development:** 25% of revenue (2024) **Planned Market Launches:** 3 new drugs by 2026 **Investments in Biotechnology:** 500 million euros (2023-2025) UCB SA pursues a growth strategy that is strongly focused on research and development (R&D). The company invests around...

Which raw materials are imported and from which countries?

**Main raw materials:** Chemicals, biological materials **Countries of origin:** USA, Germany, China UCB SA, a globally active biopharmaceutical company, imports a variety of raw materials necessary for the production of their medicines and biopharmaceutical products. The most important materials...

How strong is the company’s competitive advantage?

**Market share in neurology:** 20% (2024, estimated) **Research & Development (R&D) expenses:** 1.5 billion euros (2024) **Patent portfolio:** Over 1000 active patents (2024) UCB SA has a significant competitive advantage, especially in the field of neurology, where the company holds an...

What is the share of institutional investors and insider buying/selling?

**Institutional investor share:** Approx. 70% (estimated for 2025 based on historical data) **Insider trades:** No significant transactions in the last year (2024) UCB SA has traditionally had a high institutional investor share, which has hovered around 70% in recent years. This reflects the conf...

What percentage market share does UCB have?

**Market share of UCB SA:** Estimated 3-5% in the global pharmaceutical market (2025) **Main competitors and their market share:** 1. **Pfizer Inc.:** 10-12% 2. **Roche Holding AG:** 8-10% 3. **Novartis AG:** 8-10% 4. **Johnson & Johnson:** 7-9% 5. **Merck & Co., Inc.:** 6-8% 6. **Sanofi:**...

Is UCB stock currently a good investment?

**Revenue growth:** 8% (2024) **R&D expenses:** 25% of revenue (2024) **New product approvals:** 3 significant approvals (2024) UCB SA recorded a revenue growth of 8% in 2024, attributed to successful market launches of new products and a strong pipeline. The company continues to heavily invest...

Does UCB pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.8% (2024) UCB SA recorded a dividend yield of 1.8% in 2024. The company has a tradition of regularly paying dividends, indicating a certain level of reliability. In recent years, UCB SA has consistently increased its dividend, suggesting solid financial health and a stable bu...

New support ticket

Explore

UCB Stock Value

UCB Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does UCB do?

UCB Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

UCB Stock Value

UCB Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does UCB do?

UCB Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.